Latest news

Thumbnail image for NICE nod for GSK’s ‘bubble baby syndrome’ gene therapy

NICE nod for GSK’s ‘bubble baby syndrome’ gene therapy

The National Institute for Health and Care Excellence has published draft guidance recommending GlaxoSmithKline’s gene therapy Strimvelis as an option for treating an ultra-rare immune deficiency condition commonly referred to as bubble baby syndrome.

23rd October 2017

Thumbnail image for Two new approvals for Janssen’s Simponi Aria

Two new approvals for Janssen’s Simponi Aria

US regulators have expanded the scope of Janssen Biotech’s Simponi Aria to include the treatment of adults with active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS).

23rd October 2017

Thumbnail image for Celgene pulls plug on Crohn’s disease trials

Celgene pulls plug on Crohn’s disease trials

Celgene is abandoning late-stage testing of its experimental drug mongersen for Crohn’s disease after a Data Monitoring Committee concluded that it would be futile to continue.

20th October 2017

Thumbnail image for NICE no for Opdivo in urothelial carcinoma

NICE no for Opdivo in urothelial carcinoma

The National Institute for Health and Care Excellence has published draft guidelines rejecting NHS funding for Bristol-Myers Squibb’s Opdivo as a treatment for locally advanced unresectable or metastatic urothelial carcinoma (mUC).

20th October 2017

Thumbnail image for Speedy review for AZ’ Lynparza in breast cancer

Speedy review for AZ’ Lynparza in breast cancer

AstraZeneca’s and MSD’s Lynparza is being given a priority review by US regulators as a potential treatment for breast cancer, marking the first time a PARP inhibitor has been filed for an indication outside of ovarian cancer.

19th October 2017

Previous  --   15 16 17 18 19 20 21 22 23 24   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download